Findings from a phase IIa global trial found rituximab to be generally safe, well-tolerated and effective in the treatment of granulomatosis with polyangiitis or microscopic polyangiitis in pediatric patients.
A retrospective study found that patients with follicular lymphoma who achieved only partial remission with bendamustine plus rituximab remained in remission longer if they received maintenance rituximab.
Study findings support the addition of a conventional maintenance agent, in the absence of contraindications, with rituximab to reduce the risk of relapse in granulomatosis with polyangiitis patients.
Addition of a conventional maintenance agent to rituximab and glucocorticoids reduced the incidence of GPA relapse without resulting in a higher incidence of adverse events in study.
MS specialists share evidence-based answers on issues from ranging from contraception and conception to breastfeeding, with particular attention to the safety of various disease-modifying therapies.
Case report: A 30-year-old patient experiences progressive sensory loss starting with his hands. Collaboration between Cleveland Clinic neurologists and rheumatologists leads to diagnosis and treatment.
Cleveland Clinic rheumatologist Emily Littlejohn, DO, reviews promising new treatments for lupus.
In this case study, specialist look more closely at a patient suspected of having central nervous system vasculitis.
Two experts address the impact of disease course on therapy, general instructions for patients, individualizing treatment, thymectomy, newer selective immunotherapies and more.
A major randomized trial comparing escalation of disease-modifying therapy versus early highly effective treatment is being extended from three to six years with an enhanced focus on clinical endpoints.